{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:21Z","timestamp":1788957381924,"version":"build-2803163510"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009471","name":"Stiftelsen Dam","doi-asserted-by":"publisher","award":["\u200b\u200b2022\/FO387021"],"award-info":[{"award-number":["\u200b\u200b2022\/FO387021"]}],"id":[{"id":"10.13039\/100009471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to assess antibody responses and COVID-19 outcomes after vaccination in people with multiple sclerosis (pwMS) receiving disease-modifying therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NevroVAX is a Norwegian multicentre cohort study including 3559 pwMS and 449 healthy controls (HCs) who received at least one dose of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna) or ChAdOx1 (AstraZeneca\/Oxford) between January 2021 and December 2022. Data from records, registries, questionnaires and blood samples collected June 2021\u2013November 2023 were analysed. Primary outcomes were humoral immune responses assessed by seroconversion (anti-spike and anti-receptor-binding domain (RBD) IgG \u22655 binding antibody units\/mL). Secondary outcomes included quantitative anti-RBD IgG levels, breakthrough SARS-CoV-2 infection, COVID-19-related hospitalisation and death. Associations with breakthrough infection were evaluated using multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3559 pwMS, 1201 received anti-CD20 monoclonal antibodies and 324 sphingosine-1-phosphate receptor (S1PR) modulators. After three vaccine doses, seroconversion was observed in 43.0% of anti-CD20-treated patients and 48.4% of S1PR-treated patients. In multivariable analysis, seroconversion was associated with lower risk of breakthrough infection (OR 0.67, 95% CI 0.58 to 0.78). During follow-up, 58 pwMS (1.6%) were hospitalised for COVID-19; 4 (0.1%) required non-invasive ventilatory support, no patients required invasive ventilation and no deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Humoral vaccine responses were impaired in pwMS receiving anti-CD20 or S1PR therapies, but severe COVID-19 was rare. These findings support continued vaccination programmes and tailored protective measures for immunomodulated populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001556","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:50:13Z","timestamp":1773327013000},"page":"e001556","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0961-9350","authenticated-orcid":false,"given":"Tilde Harridsleff","family":"Rasmussen","sequence":"first","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Schikora-Rustad","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"},{"name":"Department of Neurology, S\u00f8rlandet Sykehus HF, Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5slaug Rudjord","family":"Lorentzen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"},{"name":"Department of Neurology, S\u00f8rlandet Sykehus HF, Kristiansand, Norway"},{"name":"The Norwegian National Advisory Unit on Tick-borne diseases, S\u00f8rlandet sykehus HF Arendal, Arendal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"The Trung","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias H","family":"\u00d8ver\u00e5s","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuro Sys-Med, Haukeland University Hospital, Bergen, Norway"},{"name":"University of Bergen Department of Clinical Medicine 1, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-7686","authenticated-orcid":false,"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuro Sys-Med, Haukeland University Hospital, Bergen, Norway"},{"name":"University of Bergen Department of Clinical Medicine 1, Bergen, Norway"},{"name":"Norwegian MS-Registry and Biobank, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Aarseth","sequence":"additional","affiliation":[{"name":"Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"B\u00f8","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuro Sys-Med, Haukeland University Hospital, Bergen, Norway"},{"name":"University of Bergen Department of Clinical Medicine 1, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone","family":"Berge","sequence":"additional","affiliation":[{"name":"Department of Research, Innovation and Education, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar August","family":"H\u00f8gest\u00f8l","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"},{"name":"Department of Psychology, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne F","family":"Harbo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Therese","family":"Tveter","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital Department of Rheumatology, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Kaasen","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"},{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celin\u00e9","family":"Cunen","sequence":"additional","affiliation":[{"name":"Centre for Biostatistics and Epidemiology (OCBE), Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuro Sys-Med, Haukeland University Hospital, Bergen, Norway"},{"name":"University of Bergen Department of Clinical Medicine 1, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trygve","family":"Holm\u00f8y","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"},{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Akershus, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9127-6488","authenticated-orcid":false,"given":"Elisabeth Gulowsen","family":"Celius","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Torgils","family":"Vaage","sequence":"additional","affiliation":[{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro Owren","family":"Nygaard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fridtjof","family":"Lund-Johansen","sequence":"additional","affiliation":[{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-9804","authenticated-orcid":false,"given":"Marton","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026051208152688000_8.1.e001556.1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200164","article-title":"Multiple Sclerosis, Disease-Modifying Therapies, and Infections","volume":"10","author":"Langer-Gould","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026051208152688000_8.1.e001556.2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026051208152688000_8.1.e001556.3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/13524585211026272","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry","volume":"28","author":"Spelman","year":"2022","journal-title":"Mult Scler"},{"key":"2026051208152688000_8.1.e001556.4","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7"},{"key":"2026051208152688000_8.1.e001556.5","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004228"},{"key":"2026051208152688000_8.1.e001556.6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.824926","article-title":"Therapeutic Advances in Multiple Sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Neurol"},{"key":"2026051208152688000_8.1.e001556.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm3425"},{"key":"2026051208152688000_8.1.e001556.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591&ndash;021&ndash;01540-1"},{"key":"2026051208152688000_8.1.e001556.9","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211012835","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026051208152688000_8.1.e001556.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327612"},{"key":"2026051208152688000_8.1.e001556.11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamaneurol.2021.5109","article-title":"Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination","volume":"79","author":"K\u00f6nig","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026051208152688000_8.1.e001556.12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjh.18149","article-title":"Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination","volume":"197","author":"Riise","year":"2022","journal-title":"Br J Haematol"},{"key":"2026051208152688000_8.1.e001556.13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165111","article-title":"T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis","volume":"8","author":"Wolf","year":"2023","journal-title":"JCI Insight"},{"key":"2026051208152688000_8.1.e001556.14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2026051208152688000_8.1.e001556.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02587-8","article-title":"The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study","volume":"20","author":"Christensen","year":"2022","journal-title":"BMC Med"},{"key":"2026051208152688000_8.1.e001556.16","unstructured":"Timeline: news from norwegian ministries about the coronavirus disease COVID-19 government.no2024. 2024. Available: https:\/\/www.regjeringen.no\/no\/tema\/helse-og-omsorg\/folkehelse\/tidslinje-koronaviruset\/id2692402\/"},{"key":"2026051208152688000_8.1.e001556.17","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.vaccine.2023.02.038","article-title":"Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities","volume":"41","author":"Smits","year":"2023","journal-title":"Vaccine (Auckl)"},{"key":"2026051208152688000_8.1.e001556.18","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051208152688000_8.1.e001556.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-024-09670-w","article-title":"Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults","volume":"24","author":"Tunheim","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026051208152688000_8.1.e001556.20","unstructured":"IBM SPSS statistics for windows, version 29.0. Armonk, NY IBM Corp; 2022."},{"key":"2026051208152688000_8.1.e001556.21","unstructured":"R: a language and environment for statistical computing. Vienna, Austria R Foundation for Statistical Computing; 2024."},{"key":"2026051208152688000_8.1.e001556.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105770"},{"key":"2026051208152688000_8.1.e001556.23","doi-asserted-by":"crossref","first-page":"102439","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: A review","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2026051208152688000_8.1.e001556.24","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26251"},{"key":"2026051208152688000_8.1.e001556.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001210","article-title":"Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosis","volume":"7","author":"Shawe-Taylor","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"2026051208152688000_8.1.e001556.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10951-6"},{"key":"2026051208152688000_8.1.e001556.27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330757"},{"key":"2026051208152688000_8.1.e001556.28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330100"},{"key":"2026051208152688000_8.1.e001556.29","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1007\/s00415-023-11935-4","article-title":"Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies","volume":"270","author":"Spierer","year":"2023","journal-title":"J Neurol"},{"key":"2026051208152688000_8.1.e001556.30","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1007\/s10787-023-01349-z","article-title":"Systematic review and meta-analysis of anti-CD20 treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes","volume":"31","author":"Kow","year":"2023","journal-title":"Inflammopharmacology"},{"key":"2026051208152688000_8.1.e001556.31","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221102918"},{"key":"2026051208152688000_8.1.e001556.32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001105","article-title":"COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context","volume":"9","author":"Sormani","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026051208152688000_8.1.e001556.33","unstructured":"Folkehelseinstituttet . Risikovurdering vedr\u00f8rende COVID-19: endret 1. Folkehelseinstituttet; 2022."},{"key":"2026051208152688000_8.1.e001556.34","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003545","article-title":"Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study","volume":"10","author":"\u00d8rbo","year":"2024","journal-title":"RMD Open"},{"key":"2026051208152688000_8.1.e001556.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102035","article-title":"Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study","volume":"60","author":"Hovd","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026051208152688000_8.1.e001556.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11575-8"},{"key":"2026051208152688000_8.1.e001556.37","doi-asserted-by":"crossref","first-page":"104425","DOI":"10.1016\/j.msard.2022.104425","article-title":"The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination","volume":"69","author":"Baker","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2026051208152688000_8.1.e001556.38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/14034948241253690","article-title":"New insights into the paradox between smoking and the risk of SARS-CoV-2 infection (COVID-19): Insufficient evidence for a causal association","volume":"53","author":"Kramer","year":"2025","journal-title":"Scand J Public Health"},{"key":"2026051208152688000_8.1.e001556.39","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2188857","article-title":"Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study","volume":"19","author":"Hansen","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2026051208152688000_8.1.e001556.40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:16:18Z","timestamp":1778598978000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2026-001556"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001556","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}